Jim Simons
PCVX icon

Jim Simons’s Vaxcyte PCVX Stock Holding History

Jim Simons’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.18M Sell
54,734
-10,477
-16% -$569K 0.01% 1634
2025
Q4 		$3.01M Sell
65,211
-15,266
-19% -$683K ﹤0.01% 1624
2025
Q3 		$2.9M Sell
80,477
-188,600
-70% -$6.25M ﹤0.01% 1821
2025
Q2 		$8.75M Buy
269,077
+72,800
+37% +$2.39M 0.01% 1144
2025
Q1 		$7.41M Buy
196,277
+142,200
+263% +$11.4M 0.01% 1181
2024
Q4 		$4.43M Buy
+54,077
New +$5.37M 0.01% 1522
2023
Q3 		– Sell
-215,477
Closed -$10.8M – 3977
2023
Q2 		$10.8M Sell
215,477
-205,400
-49% -$9.74M 0.02% 984
2023
Q1 		$15.8M Sell
420,877
-101,100
-19% -$4.29M 0.02% 849
2022
Q4 		$25M Buy
521,977
+428,777
+460% +$16.8M 0.03% 607
2022
Q3 		$2.24M Buy
93,200
+20,600
+28% +$522K ﹤0.01% 1944
2022
Q2 		$1.58M Buy
72,600
+31,800
+78% +$736K ﹤0.01% 2366
2022
Q1 		$985K Buy
40,800
+27,800
+214% +$607K ﹤0.01% 2735
2021
Q4 		$309K Buy
+13,000
New +$302K ﹤0.01% 3333

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jim Simons's PCVX Position: Q1 2026 in Review

Jim Simons reduced its Vaxcyte (PCVX) stake by 16% in Q1 2026, selling an estimated $569K and leaving 54,734 shares worth $3.18M. The position accounts for 0.01% of the portfolio, ranked #1634.

Jim Simons first reported a position in PCVX in Q4 2021 and has held it in 13 quarters since. The position peaked at $25M in Q4 2022. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Jim Simons held 54,734 shares of Vaxcyte worth $3.18M as of Q1 2026.
  • Jim Simons sold 10,477 Vaxcyte shares in Q1 2026, an estimated $569K.
  • Vaxcyte made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1634 holding.
  • Jim Simons first reported a position in Vaxcyte in Q4 2021 and has held it in 13 quarters since.
  • Jim Simons's Vaxcyte position peaked at $25M in Q4 2022.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.